The Bandage Contact Lenses Market continues to expand as detailed research into consumer behavior reveals increasing patient preference for comfort-oriented and therapeutic lenses. Patients recovering from corneal injuries or surgery are seeking lenses that provide both healing and pain relief. Ophthalmologists are recommending bandage lenses more frequently due to their ability to...

Market Overview The global dry eye syndrome market size was valued at USD 7.30 billion in 2024 and is projected to grow from USD 7.81 billion in 2025 to reach USD 13.34 billion by 2033, exhibiting a CAGR of 6.92% during the forecast period (2025–2033).  The global Dry Eye Syndrome market continues to evolve rapidly, driven by shifting consumer...

  Clinical practice patterns in dry age-related macular degeneration management are undergoing significant evolution as the medical community anticipates the arrival of disease-modifying pharmacological treatments that could fundamentally alter the therapeutic landscape currently dominated by nutritional supplementation and lifestyle modification recommendations. The dry age related...

Ocular Fluorometholone Market Overview The Ocular Fluorometholone Market is witnessing steady growth as demand increases for mild-to-moderate corticosteroid therapies in ophthalmic care. Ocular fluorometholone is a synthetic corticosteroid commonly prescribed to treat inflammatory conditions of the eye, including allergic conjunctivitis, uveitis, and postoperative inflammation. Its...

Ocular Bromfenac Market Overview The Ocular Bromfenac Market is witnessing steady growth as the demand for effective nonsteroidal anti-inflammatory drugs (NSAIDs) in ophthalmic care continues to rise. Ocular bromfenac is widely used to manage postoperative inflammation and pain following eye surgeries, particularly cataract procedures. Its strong anti-inflammatory properties,...

4 gene therapy trials showing curative potential for hepatic copper in 2026 As 2026 begins, the global hepatology community is closely monitoring a wave of breakthrough data from Phase II and III trials that aim to permanently correct the ATP7B genetic mutation. Regulatory authorities in the European Union and the United States have recently signaled a willingness to accept biomarker-driven...